JP6026708B1 - コンドロイチン硫酸誘導体及び膀胱疾患処置剤 - Google Patents

コンドロイチン硫酸誘導体及び膀胱疾患処置剤 Download PDF

Info

Publication number
JP6026708B1
JP6026708B1 JP2016517573A JP2016517573A JP6026708B1 JP 6026708 B1 JP6026708 B1 JP 6026708B1 JP 2016517573 A JP2016517573 A JP 2016517573A JP 2016517573 A JP2016517573 A JP 2016517573A JP 6026708 B1 JP6026708 B1 JP 6026708B1
Authority
JP
Japan
Prior art keywords
group
carbon atoms
spacer
steroid
chondroitin sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016517573A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2016111356A1 (ja
Inventor
宗外 成田
宗外 成田
貴弘 畠中
貴弘 畠中
裕子 吉田
裕子 吉田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Application granted granted Critical
Publication of JP6026708B1 publication Critical patent/JP6026708B1/ja
Publication of JPWO2016111356A1 publication Critical patent/JPWO2016111356A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
JP2016517573A 2015-01-09 2016-01-08 コンドロイチン硫酸誘導体及び膀胱疾患処置剤 Active JP6026708B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015003572 2015-01-09
JP2015003572 2015-01-09
PCT/JP2016/050526 WO2016111356A1 (ja) 2015-01-09 2016-01-08 コンドロイチン硫酸誘導体及び膀胱疾患処置剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016200801A Division JP6748551B2 (ja) 2015-01-09 2016-10-12 コンドロイチン硫酸誘導体及び膀胱疾患処置剤

Publications (2)

Publication Number Publication Date
JP6026708B1 true JP6026708B1 (ja) 2016-11-16
JPWO2016111356A1 JPWO2016111356A1 (ja) 2017-04-27

Family

ID=56356041

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016517573A Active JP6026708B1 (ja) 2015-01-09 2016-01-08 コンドロイチン硫酸誘導体及び膀胱疾患処置剤
JP2016200801A Active JP6748551B2 (ja) 2015-01-09 2016-10-12 コンドロイチン硫酸誘導体及び膀胱疾患処置剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016200801A Active JP6748551B2 (ja) 2015-01-09 2016-10-12 コンドロイチン硫酸誘導体及び膀胱疾患処置剤

Country Status (8)

Country Link
US (2) US10350236B2 (cg-RX-API-DMAC10.html)
EP (2) EP3757136B1 (cg-RX-API-DMAC10.html)
JP (2) JP6026708B1 (cg-RX-API-DMAC10.html)
KR (2) KR102655779B1 (cg-RX-API-DMAC10.html)
CN (1) CN107108761B (cg-RX-API-DMAC10.html)
CA (1) CA2972866C (cg-RX-API-DMAC10.html)
ES (1) ES2828692T3 (cg-RX-API-DMAC10.html)
WO (1) WO2016111356A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350236B2 (en) * 2015-01-09 2019-07-16 Seikagaku Corporation Chondroitin sulfate derivative and agent for treating bladder diseases
JP7660066B2 (ja) * 2019-10-03 2025-04-10 生化学工業株式会社 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム
RU2751649C1 (ru) * 2020-08-24 2021-07-15 Наталья Геннадиевна Галкина Способ лечения и профилактики цистита
AU2022348759A1 (en) * 2021-09-16 2024-01-25 Coval Biopharma (Shanghai) Co., Ltd. Drug delivery system for locally delivering therapeutic agents and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539306A (ja) * 1990-12-14 1993-02-19 D D S Kenkyusho:Kk ヒアルロン酸およびコンドロイチン誘導体
JP2000501082A (ja) * 1995-11-30 2000-02-02 ハミルトン シビック ホスピタルズ リサーチ デベロップメント，インコーポレイテッド グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体
WO2005066214A1 (ja) * 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
JP2006504747A (ja) * 2002-10-18 2006-02-09 フィディア ファルマチェウティチ ソシエタ ペル アチオニ ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類
JP2009503090A (ja) * 2005-08-03 2009-01-29 モリア・バイオファーマシューティカルズ 嚢胞性線維症における脂質複合体の使用及びその適用
WO2015005458A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
WO2015005459A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 呼吸器投与用の医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US20040161476A1 (en) * 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
IE20070900A1 (en) * 2007-12-12 2009-06-24 Eurand Pharmaceuticals Ltd New anticancer conjugates
JP2015003572A (ja) 2013-06-20 2015-01-08 トヨタ紡織株式会社 乗物用シート
US10350236B2 (en) * 2015-01-09 2019-07-16 Seikagaku Corporation Chondroitin sulfate derivative and agent for treating bladder diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539306A (ja) * 1990-12-14 1993-02-19 D D S Kenkyusho:Kk ヒアルロン酸およびコンドロイチン誘導体
JP2000501082A (ja) * 1995-11-30 2000-02-02 ハミルトン シビック ホスピタルズ リサーチ デベロップメント，インコーポレイテッド グリコサミノグリカン―アンチトロンビンｉｉｉ／ヘパリン補因子ｉｉ結合体
JP2006504747A (ja) * 2002-10-18 2006-02-09 フィディア ファルマチェウティチ ソシエタ ペル アチオニ ヒアルロン酸又はヒアルロン酸誘導体に共有結合したタキサン類
WO2005066214A1 (ja) * 2004-01-07 2005-07-21 Seikagaku Corporation ヒアルロン酸誘導体及びそれを含む薬剤
JP2009503090A (ja) * 2005-08-03 2009-01-29 モリア・バイオファーマシューティカルズ 嚢胞性線維症における脂質複合体の使用及びその適用
WO2015005458A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
WO2015005459A1 (ja) * 2013-07-10 2015-01-15 生化学工業株式会社 呼吸器投与用の医薬組成物

Also Published As

Publication number Publication date
EP3243841A4 (en) 2018-07-11
KR20230047193A (ko) 2023-04-06
JP2017036455A (ja) 2017-02-16
US10350236B2 (en) 2019-07-16
EP3757136B1 (en) 2023-07-19
CN107108761A (zh) 2017-08-29
JPWO2016111356A1 (ja) 2017-04-27
WO2016111356A1 (ja) 2016-07-14
US10953037B2 (en) 2021-03-23
KR20170098942A (ko) 2017-08-30
CA2972866A1 (en) 2016-07-14
JP6748551B2 (ja) 2020-09-02
ES2828692T3 (es) 2021-05-27
US20170354675A1 (en) 2017-12-14
EP3757136A1 (en) 2020-12-30
KR102512431B1 (ko) 2023-03-22
EP3243841A1 (en) 2017-11-15
CN107108761B (zh) 2020-06-30
CA2972866C (en) 2023-08-22
KR102655779B1 (ko) 2024-04-05
US20190282607A1 (en) 2019-09-19
EP3243841B1 (en) 2020-09-30

Similar Documents

Publication Publication Date Title
US10953037B2 (en) Chondroitin sulfate derivative and agent for treating bladder diseases
US20260014072A1 (en) Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
US10098962B2 (en) Glycosaminoglycan derivative and method for producing same
CN108350022A (zh) 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法
EP3020417A1 (en) Pharmaceutical composition for respiratory administration
WO2005085294A1 (ja) ヒアルロン酸−メトトレキサート結合体
JP2025094276A (ja) 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤
HK40039515A (en) Chondroitin sulfate derivative and agent for treating bladder diseases
EP2017289A1 (en) Pharmaceutical composition for conformational disease
WO2025151884A1 (en) Use of glycosaminoglycan sulfated polysaccharides such as sodium pentosan polysulfate in combination with permeation agents to treat alzheimer's disease
HK1217300B (en) Treatment of oculopharyngeal muscular dystrophy by intravenous administration of trehalose

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160325

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160325

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160913

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161012

R150 Certificate of patent or registration of utility model

Ref document number: 6026708

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250